Performance of 68Ga-PSMA PET/CT for prostate cancer management at initial staging and time of biochemical recurrence
Current Urology Reports Sep 15, 2017
Bailey J, et al. - Researchers conducted an imaging study which indicated that Gallium-68 labeled PSMA-ligands such as HBED-CC (68Ga-PSMA) offers significant promise for both, primary disease and biochemically recurrent prostate cancer. Moreover, the evidence base to support 68Ga-PSMA is nevertheless still underdeveloped, and more rigorous studies substantiating efficacy are required.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
